Which Acute Myeloid Leukemia Patients Should Be Offered Transplantation?

Brissot, Éolia; Mohty, Mohamad

doi:10.1053/j.seminhematol.2015.03.001

Cited by 8 publications

(4 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we aimed to investigate the effects of IFITM on AML survival. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for AML, which can reduce recurrence and prolong the survival by significantly reducing the leukemia residual disease [19]. Herein, we also analyzed whether allo-HSCT could overcome the prognostic effects of the IFITM family.…”

Section: Introductionmentioning

confidence: 99%

High IFITM3 expression predicts adverse prognosis in acute myeloid leukemia

et al. 2019

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is a malignancy caused by the uncontrolled and dysregulated clonal expansion of abnormal myeloid primordial cells. In general, the prognosis of AML remains poor despite new discoveries in its pathogenesis and treatment. It is crucial to find early and sensitive biomarkers and continue to explore active targeted treatments. Interferoninduced transmembrane protein (IFITM) family is an important part of the interferon signaling pathway and participate in the regulation of immune cell signaling, adhesion, cancer, and liver cell migration. However, the clinical and prognostic value of the IFITM family in AML has rarely been studied. We screened The Cancer Genome Atlas database and found 155 AML patients with IFITM family (IFITM1-5) expression data. In patients who only received chemotherapy, those with high IFITM3 expression had significantly shorter event-free survival (EFS) and overall survival (OS) than patients with low expression (all P < 0.05). Multivariate analysis demonstrated that high IFITM3 expression was an independent risk factor for EFS and OS in patients only received chemotherapy (all P < 0.05). In patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT), however, all IFITM members had no impact on either EFS or OS. In conclusion, our study elucidated that high IFITM3 expression could be an adverse prognostic factor for AML, whose effect might be overcome by allo-HSCT.

show abstract

Section: Introductionmentioning

confidence: 99%

High IFITM3 expression predicts adverse prognosis in acute myeloid leukemia

et al. 2019

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4][5] With the improvement of conditioning chemotherapy and supportive care, the outcome of this strategy has improved. 6 Yet a major issue remains, which is the quest for a fully-matched donor.…”

mentioning

confidence: 99%

Longer delay of hematological recovery and increased transfusion needs after haploidentical compared to non-haploidentical stem cell transplantation

Desjonqueres

Illiaquer²,

Duquesne

et al. 2016

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…In this study, we focus on investigating the effects of HMGNs on the survival of AML patients. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment to reduce relapse of AML and prolong survival time via significant reduction of leukemia residual disease [16]. Here we also analyzed whether allo-HSCT can overcome the prognostic effects of HMGN family expression.…”

Section: Futurementioning

confidence: 99%

Prognostic Value of HMGN Family Expression in Acute Myeloid Leukemia

et al. 2021

View full text Add to dashboard Cite

Aim: The objective of this work was to investigate the prognostic role of the HMGN family in acute myeloid leukemia (AML). Methods: A total of 155 AML patients with HMGN1–5 expression data from the Cancer Genome Atlas database were enrolled in this study. Results: In the chemotherapy-only group, patients with high HMGN2 expression had significantly longer event-free survival (EFS) and overall survival (OS) than those with low expression (all p < 0.05), whereas high HMGN5 expressers had shorter EFS and OS than the low expressers (all p < 0.05). Multivariate analysis identified that high HMGN2 expression was an independent favorable prognostic factor for patients who only received chemotherapy (all p < 0.05). HMGN family expression had no impact on EFS and OS in AML patients receiving allogeneic hematopoietic stem cell transplantation. Conclusion: High HMGN2/5 expression is a potential prognostic indicator for AML.

show abstract

Which Acute Myeloid Leukemia Patients Should Be Offered Transplantation?

Cited by 8 publications

References 86 publications

High IFITM3 expression predicts adverse prognosis in acute myeloid leukemia

High IFITM3 expression predicts adverse prognosis in acute myeloid leukemia

Longer delay of hematological recovery and increased transfusion needs after haploidentical compared to non-haploidentical stem cell transplantation

Prognostic Value of HMGN Family Expression in Acute Myeloid Leukemia

Contact Info

Product

Resources

About